Plain-English translation of NCT05639413 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is a research study that follows patients with advanced colorectal cancer that has a specific genetic change called a BRAF V600E mutation. Researchers will collect blood samples and medical information from you over time as you receive your regular cancer treatments. The goal is to understand why some patients respond well to treatment while others develop resistance, so doctors can make better decisions about care in the future.
Advanced colorectal cancer with this particular genetic mutation is rare and difficult to treat — most patients eventually stop responding to available medications. By tracking patients' blood samples and treatment outcomes over time, researchers hope to identify warning signs of treatment resistance early and discover which patients might benefit from different approaches.
You likely qualify if…
You likely don't qualify if…
You will give blood samples at specific times during your cancer treatment — at the start of treatment cycles and at follow-up visits (at 3 and 6 months). In total, you may give up to about 390 milliliters (roughly 13 ounces) of blood across the entire study. Your doctors will also share your medical records and treatment outcomes with the research team as part of your regular cancer care. The study will continue as long as you are receiving treatment for your cancer.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
France